Anti-BCMA chimeric antigen receptor

Patent metadata

Field	Value
Publication number	US-11084880-B2
Application number	US-201816197565-A
Country	US
Kind code	B2
Filing date	Nov 21, 2018
Priority date	Jul 21, 2014
Publication date	Aug 10, 2021
Grant date	Aug 10, 2021

Abstract

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

First claim

What is claimed is:

1. An isolated chimeric antigen receptor (CAR) polypeptide, wherein the CAR polypeptide comprises an antibody or antibody fragment which comprises an anti-B-cell maturation antigen (BCMA) binding domain, a transmembrane domain, and an intracellular signaling domain, wherein said anti-BCMA binding domain comprises:
(i) a heavy chain complementary determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO: 394, a heavy chain complementary determining region 2 (HC CDR2) comprising the amino acid sequence of SEQ ID NO: 434, a heavy chain complementary determining region 3 (HC CDR3) comprising the amino acid sequence of SEQ ID NO: 474, a light chain complementary determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO: 514, a light chain complementary determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO: 554, and a light chain complementary determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO: 594;
(ii) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 634, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 674, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 714, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 754, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 794, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 834; or
(iii) a HC CDR1 comprising the amino acid sequence of SEQ ID NO: 874, a HC CDR2 comprising the amino acid sequence of SEQ ID NO: 914, a HC CDR3 comprising the amino acid sequence of SEQ ID NO: 954, a LC CDR1 comprising the amino acid sequence of SEQ ID NO: 994, a LC CDR2 comprising the amino acid sequence of SEQ ID NO: 1034, and a LC CDR3 comprising the amino acid sequence of SEQ ID NO: 1074; and
wherein the intracellular signaling domain comprises a primary signaling domain comprising a functional signaling domain of CD3 zeta or an amino acid sequence with 95-99% identity thereof.

2. The isolated CAR polypeptide of claim 1 , comprising:
(i) the amino acid sequence of a light chain variable region comprising the amino acid sequence of SEQ ID NO: 94;
(ii) an amino acid sequence having at least one, two or three modifications but not more than 30, 20, or 10 modifications of the amino acid sequence of a light chain variable region comprising the amino acid sequence of SEQ ID NO: 94; or
(iii) an amino acid sequence with at least 95% identity to the amino acid sequence of a light chain variable region comprising the amino acid sequence of SEQ ID NO: 94.

3. The isolated CAR polypeptide of claim 1 , comprising:
(i) the amino acid sequence of a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 79;
(ii) an amino acid sequence having at least one, two or three modifications but not more than 30, 20, or 10 modifications of the amino acid sequence of a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 79; or
(iii) an amino acid sequence with at least 95% identity to the amino acid sequence of a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 79.

4. The isolated CAR polypeptide of claim 1 , comprising the amino acid sequence of a light chain variable region comprising the amino acid sequence of SEQ ID NO: 94, and the amino acid sequence of a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 79.

5. The isolated CAR polypeptide of claim 1 , comprising:
(i) the amino acid sequence of SEQ ID NO: 49;
(ii) an amino acid sequence having at least one, two or three modifications but not more than 30, 20, or 10 modifications to SEQ ID NO: 49; or
(iii) an amino acid sequence with at least 95% identity to SEQ ID NO: 49.

6. The isolated CAR polypeptide of claim 1 , wherein the transmembrane domain comprises a transmembrane domain from a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, and CD154.

7. The isolated CAR polypeptide of claim 1 , wherein the transmembrane domain comprises:
(i) the amino acid sequence of SEQ ID NO: 6;
(ii) an amino acid sequence having at least one, two or three modifications but not more than 20, 10, or 5 modifications of the amino acid sequence of SEQ ID NO: 6; or
(iii) a sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 6.

8. The isolated CAR polypeptide of claim 1 , wherein the anti-BCMA binding domain is connected to the transmembrane domain by a hinge region.

9. The isolated CAR polypeptide of claim 8 , wherein the hinge region comprises the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 36, or a sequence with at least 95% identity thereto.

10. The isolated CAR polypeptide of claim 1 , wherein the intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain comprises a functional signaling domain derived from a protein selected from the group consisting of MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CDS, ICAM-1, 4-1BB (CD137), B7-H3, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, and a ligand that specifically binds with CD83.

11. The isolated CAR polypeptide of claim 1 , wherein the intracellular signaling domain comprises a costimulatory domain, wherein the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 7, or a sequence with at least 95% identity to the amino acid sequence of SEQ ID NO: 7.

12. The isolated CAR polypeptide of claim 1 , wherein the intracellular signaling domain comprises a functional signaling domain of 4-1BB and/or a functional signaling domain of CD3 zeta.

13. The isolated CAR polypeptide of claim 1 , wherein the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 7 and/or the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10, or a sequence with 95-99% identity to the amino acid sequence of SEQ ID NO: 7 and/or the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10.

14. The isolated CAR polypeptide of claim 1 , wherein the intracellular signaling domain comprises the amino acid sequence of SEQ ID NO: 7 and the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10, wherein the sequences comprising the intracellular signaling domain are expressed in the same frame and as a single polypeptide chain.

15. The isolated CAR polypeptide of claim 1 , further comprising a leader sequence which comprises the amino acid sequence of SEQ ID NO: 1.

16. The isolated CAR polypeptide of claim 1 , comprising:
(i) the amino acid sequence of SEQ ID NO: 109;
(ii) an amino acid sequence having at least one, two, or three modifications but not more than 30, 20, or 10 modifications to SEQ ID NO: 109; or
(iii) an amino acid sequence wi

Assignees

• Novartis Ag
• Univ Pennsylvania

Inventors

• Brogdon Jennifer
• Choi Eugene
• Ebersbach Hilmar Erhard
• Glass David Jonathan
• Huet Heather
• June Carl H
• Mannick Joan
• Milone Michael C
• Murphy Leon
• Plesa Gabriela
• Richardson Celeste
• Ruella Marco
• Singh Reshma
• Wang Yongqiang
• Wu Qilong

Classifications

• A61K40/11 Primary

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• C07K2319/74

  containing a fusion for binding to a cell surface receptor · CPC title

• C07K2319/33

  fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies · CPC title

• C07K2319/03

  containing a transmembrane segment · CPC title

• A61P35/02

  specific for leukemia · CPC title